- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Management of myelofibrosis after ruxolitinib failure ; volume:99 ; number:6 ; day:20 ; month:3 ; year:2020 ; pages:1177-1191 ; date:6.2020
Annals of hematology ; 99, Heft 6 (20.3.2020), 1177-1191, 6.2020
- Creator
-
Harrison, Claire N.
Schaap, Nicolaas
Mesa, Ruben A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04002-9
- URN
-
urn:nbn:de:101:1-2020072319190810500694
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Harrison, Claire N.
- Schaap, Nicolaas
- Mesa, Ruben A.
- SpringerLink (Online service)
Other Objects (12)
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes